NCT06375239 Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
| NCT ID | NCT06375239 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ray Therapeutics, Inc. |
| Condition | Retinitis Pigmentosa |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-04-05 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2024-04-05 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records * Best-corrected visual acuity between 20/70 and HM in at least one eye as tested with clinic-based visual acuity method * Reasonably fluent in English Exclusion Criteria: * Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing. * Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol * Current pregnancy as reported by patient
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06375239 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Retinitis Pigmentosa. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06375239 currently recruiting?
Yes, NCT06375239 is actively recruiting participants. Contact the research team at info@vr-ai.com for enrollment information.
Where is the NCT06375239 trial being conducted?
This trial is being conducted at Irvine, United States.
Who is sponsoring the NCT06375239 clinical trial?
NCT06375239 is sponsored by Ray Therapeutics, Inc.. The trial plans to enroll 120 participants.